The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 22:27

Baiyunshan Pharmaceutical's Unit Gets Nod to Cefuroxime Sodium for Injection's Amendment

MT NewswiresDec 16 12:18

BAIYUNSHAN PH (600332.SH) subsidiary Tianxin Pharmaceutical's products have passed the consistency evaluation of generic drugs.

BAIYUNSHAN PH (600332.SH) announced that recently, the company's controlling subsidiary Guangzhou BAIYUNSHAN PH Tianxin Pharmaceutical Co., Ltd...

Zhitong FinanceDec 13 16:51

Express News | BAIYUNSHAN PH: The injectable cefazolin sodium has passed the consistency evaluation for generics.

BreakingsDec 13 16:48

HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.

HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.

Zhitong FinanceDec 13 07:20

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12 07:38